Skip to main content

Advertisement

SpringerLink
Log in

Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Cancer-associated fibroblasts (CAFs) are classified into various functional subtypes such as fibroblast activation protein-α (FAP-α), fibroblast specific protein-1 (FSP-1), platelet-derived growth factor receptor-α (PDGFR-α), and PDGFR-β. In this study, we compared the expression of CAF-related proteins in invasive lobular carcinoma (ILC) with those in invasive carcinoma of no special type (NST) and assessed the implications of the differences observed. Using tissue microarrays of 104 ILC and 524 invasive carcinoma (NST) cases, immunohistochemistry for CAF-related proteins [podoplanin, prolyl 4-hydroxylase, FAP-α, FSP-1/S100A4, PDGFR-α, PDGFR-β, and chondroitin sulfate proteoglycan (NG2)] was conducted. In invasive carcinoma (NST), tumor cells expressed a high level of PDGFR-α, whereas ILC tumor cells expressed high levels of podoplanin, prolyl 4-hydroxylase, FAP-α, and FSP-1/S100A4. In stromal cells of invasive carcinoma (NST), high expression levels of prolyl 4-hydroxylase, PDGFR-α, and NG2 were observed, whereas ILC stromal cells expressed high levels of FAP-α, FSP-1/S100A4, and PDGFR-β. In ILC, tumoral FSP-1/S100A4 positivity was associated with higher Ki-67 labeling index (p = 0.010) and non-luminal A type cancer (p = 0.014). Stromal PDGFR-α positivity was associated with lymph node metastasis (p = 0.011). On survival analysis of entire cases, tumoral FSP-1/S100A4 positivity (p = 0.002), stromal podoplanin positivity (p = 0.041), and stromal FSP-1/S100A4 negativity (p = 0.041) were associated with shorter disease-free survival; only tumoral FSP-1/S100A4 positivity (p = 0.044) was associated with shorter overall survival. In ILC, the expression of FAP-α and FSP-1/S100A4 was higher in both tumor and stromal cells than that observed in invasive carcinoma (NST). These results indicate that CAFs are a potential target in ILC treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Tavassoli FA, Devilee P, International Agency for Research on Cancer et al (2003) Pathology and genetics of tumours of the breast and female genital organs. IAPS Press, Lyon

    Google Scholar 

  2. Li CI, Anderson BO, Daling JR et al (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289(11):1421–1424

    Article  PubMed  Google Scholar 

  3. Li CI, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93(9):1046–1052. doi:10.1038/sj.bjc.6602787

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Tot T (2000) The cytokeratin profile of medullary carcinoma of the breast. Histopathology 37(2):175–181. doi:10.1046/j.1365-2559.2000.00889.x

    Article  CAS  PubMed  Google Scholar 

  5. Reeves GK, Beral V, Green J et al (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 7(11):910–918. doi:10.1016/s1470-2045(06)70911-1

    Article  CAS  PubMed  Google Scholar 

  6. Lesser ML, Rosen PP, Kinne DW (1982) Multicentricity and bilaterality in invasive breast carcinoma. Surgery 91(2):234–240

    CAS  PubMed  Google Scholar 

  7. Silverstein MJ, Lewinsky BS, Waisman JR et al (1994) Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 73(6):1673–1677

    Article  CAS  PubMed  Google Scholar 

  8. De Leeuw WJ, Berx G, Vos CB et al (1997) Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 183(4):404–411. doi:10.1002/(sici)1096-9896(199712)183:4<404:aid-path1148>3.0.co;2-9

    Article  PubMed  Google Scholar 

  9. Tsutsui S, Ohno S, Murakami S et al (2003) Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery 133(2):219–221. doi:10.1067/msy.2003.32

    Article  PubMed  Google Scholar 

  10. Uehara H, Takahashi T, Oha M et al (2014) Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int J Cancer. doi:10.1002/ijc.28903

    Google Scholar 

  11. Franco OE, Shaw AK, Strand DW et al (2010) Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 21(1):33–39. doi:10.1016/j.semcdb.2009.10.010

    Article  CAS  PubMed  Google Scholar 

  12. Ostman A (2014) Cancer-associated fibroblasts: recent developments and emerging challenges. Semin Cancer Biol 25:1–2. doi:10.1016/j.semcancer.2014.02.004

    Article  PubMed  Google Scholar 

  13. Desmouliere A, Guyot C, Gabbiani G (2004) The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 48(5–6):509–517. doi:10.1387/ijdb.041802ad

    Article  CAS  PubMed  Google Scholar 

  14. De Wever O, Nguyen QD, Van Hoorde L et al (2004) Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 18(9):1016–1018. doi:10.1096/fj.03-1110fje

    PubMed  Google Scholar 

  15. Sugimoto H, Mundel TM, Kieran MW et al (2006) Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5(12):1640–1646

    Article  CAS  PubMed  Google Scholar 

  16. Pietras K, Sjoblom T, Rubin K et al (2003) PDGF receptors as cancer drug targets. Cancer Cell 3(5):439–443

    Article  CAS  PubMed  Google Scholar 

  17. Kraman M, Bambrough PJ, Arnold JN et al (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330(6005):827–830. doi:10.1126/science.1195300

    Article  CAS  PubMed  Google Scholar 

  18. Kawase A, Ishii G, Nagai K et al (2008) Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 123(5):1053–1059. doi:10.1002/ijc.23611

    Article  CAS  PubMed  Google Scholar 

  19. Kojima Y, Acar A, Eaton EN et al (2010) Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 107(46):20009–20014. doi:10.1073/pnas.1013805107

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Cortez E, Roswall P, Pietras K (2014) Functional subsets of mesenchymal cell types in the tumor microenvironment. Semin Cancer Biol 25:3–9. doi:10.1016/j.semcancer.2013.12.010

    Article  CAS  PubMed  Google Scholar 

  21. Mao Y, Keller ET, Garfield DH et al (2013) Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 32(1–2):303–315. doi:10.1007/s10555-012-9415-3

    Article  PubMed  PubMed Central  Google Scholar 

  22. Nakagawa S, Miki Y, Miyashita M et al (2016) Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets. Breast Cancer Res Treat 155(1):65–75. doi:10.1007/s10549-015-3668-9

    Article  CAS  PubMed  Google Scholar 

  23. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410

    Article  CAS  PubMed  Google Scholar 

  24. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. doi:10.1200/jco.2009.25.6529

    Article  PubMed  PubMed Central  Google Scholar 

  25. Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi:10.1200/jco.2013.50.9984

    Article  PubMed  Google Scholar 

  26. Henry LR, Lee HO, Lee JS et al (2007) Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 13(6):1736–1741. doi:10.1158/1078-0432.ccr-06-1746

    Article  CAS  PubMed  Google Scholar 

  27. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. doi:10.1093/annonc/mdr304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Jansson S, Bendahl PO, Grabau DA et al (2014) The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRalpha, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. Plos One 9(7):e102176. doi:10.1371/journal.pone.0102176

    Article  PubMed  PubMed Central  Google Scholar 

  29. Zhu Y, Wang Y, Guan B et al (2014) C-kit and PDGFRA gene mutations in triple negative breast cancer. Int J Clin Exp Pathol 7(7):4280–4285

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Martin-Villar E, Megias D, Castel S et al (2006) Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 119(Pt 21):4541–4553. doi:10.1242/jcs.03218

    Article  CAS  PubMed  Google Scholar 

  31. Grau SJ, Trillsch F, Tonn JC et al (2015) Podoplanin increases migration and angiogenesis in malignant glioma. Int J Clin Exp Pathol 8(7):8663–8670

    PubMed  PubMed Central  Google Scholar 

  32. Xiong G, Deng L, Zhu J et al (2014) Prolyl-4-hydroxylase alpha subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer 14:1. doi:10.1186/1471-2407-14-1

    Article  PubMed  PubMed Central  Google Scholar 

  33. Wasif N, Maggard MA, Ko CY et al (2010) Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol 17(7):1862–1869. doi:10.1245/s10434-010-0953-z

    Article  PubMed  Google Scholar 

  34. Ito M, Hagiyama M, Mimae T et al (2014) alpha-Parvin, a pseudopodial constituent, promotes cell motility and is associated with lymph node metastasis of lobular breast carcinoma. Breast Cancer Res Treat 144(1):59–69. doi:10.1007/s10549-014-2859-0

    Article  CAS  PubMed  Google Scholar 

  35. Catteau X, Simon P, Noel JC (2014) Myofibroblastic stromal reaction and lymph node status in invasive breast carcinoma: possible role of the TGF-beta1/TGF-betaR1 pathway. BMC Cancer 14:499. doi:10.1186/1471-2407-14-499

    Article  PubMed  PubMed Central  Google Scholar 

  36. Song S, Ewald AJ, Stallcup W et al (2005) PDGFRbeta + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7(9):870–879. doi:10.1038/ncb1288

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Iacobuzio-Donahue CA, Argani P, Hempen PM et al (2002) The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res 62(18):5351–5357

    CAS  PubMed  Google Scholar 

  38. Shao ZM, Nguyen M, Barsky SH (2000) Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19(38):4337–4345. doi:10.1038/sj.onc.1203785

    Article  CAS  PubMed  Google Scholar 

  39. Huang Y, Simms AE, Mazur A et al (2011) Fibroblast activation protein-alpha promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis 28(6):567–579. doi:10.1007/s10585-011-9392-x

    Article  CAS  PubMed  Google Scholar 

  40. Jia J, Martin TA, Ye L et al (2014) FAP-alpha (Fibroblast activation protein-alpha) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway. BMC Cell Biol 15:16. doi:10.1186/1471-2121-15-16

    Article  PubMed  PubMed Central  Google Scholar 

  41. Jenkinson SR, Barraclough R, West CR et al (2004) S100A4 regulates cell motility and invasion in an in vitro model for breast cancer metastasis. Br J Cancer 90(1):253–262. doi:10.1038/sj.bjc.6601483

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Wang L, Wang X, Liang Y et al (2012) S100A4 promotes invasion and angiogenesis in breast cancer MDA-MB-231 cells by upregulating matrix metalloproteinase-13. Acta Biochim Pol 59(4):593–598

    CAS  PubMed  Google Scholar 

  43. Michaut M, Chin SF, Majewski I et al (2016) Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Sci Rep 6:18517. doi:10.1038/srep18517

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. O’Connell JT, Sugimoto H, Cooke VG et al (2011) VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci USA 108(38):16002–16007. doi:10.1073/pnas.1109493108

    Article  PubMed  PubMed Central  Google Scholar 

  45. Zhang J, Chen L, Liu X et al (2013) Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogens. Cancer Res 73(9):2770–2781. doi:10.1158/0008-5472.can-12-3022

    Article  CAS  PubMed  Google Scholar 

  46. Cabezon T, Celis JE, Skibshoj I et al (2007) Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer. Int J Cancer 121(7):1433–1444. doi:10.1002/ijc.22850

    Article  CAS  PubMed  Google Scholar 

  47. Zhang J, Chen L, Xiao M et al (2011) FSP1 + fibroblasts promote skin carcinogenesis by maintaining MCP-1-mediated macrophage infiltration and chronic inflammation. Am J Pathol 178(1):382–390. doi:10.1016/j.ajpath.2010.11.017

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Eusebi V, Magalhaes F, Azzopardi JG (1992) Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol 23(6):655–662

    Article  CAS  PubMed  Google Scholar 

  49. Bentz JS, Yassa N, Clayton F (1998) Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases. Mod Pathol 11(9):814–822

    CAS  PubMed  Google Scholar 

  50. Narendra S, Jenkins SM, Khoor A et al (2015) Clinical outcome in pleomorphic lobular carcinoma: a case-control study with comparison to classic invasive lobular carcinoma. Ann Diagn Pathol 19(2):64–69. doi:10.1016/j.anndiagpath.2015.01.005

    Article  PubMed  PubMed Central  Google Scholar 

  51. Simpson PT, Reis-Filho JS, Lambros MB et al (2008) Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol 215(3):231–244. doi:10.1002/path.2358

    Article  CAS  PubMed  Google Scholar 

  52. Ohlund D, Elyada E, Tuveson D (2014) Fibroblast heterogeneity in the cancer wound. J Exp Med 211(8):1503–1523. doi:10.1084/jem.20140692

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Haubeiss S, Schmid JO, Murdter TE et al (2010) Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer 9:168. doi:10.1186/1476-4598-9-168

    Article  PubMed  PubMed Central  Google Scholar 

  54. Brennen WN, Isaacs JT, Denmeade SR (2012) Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 11(2):257–266. doi:10.1158/1535-7163.mct-11-0340

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Santos AM, Jung J, Aziz N et al (2009) Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 119(12):3613–3625. doi:10.1172/jci38988

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Scott AM, Wiseman G, Welt S et al (2003) A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 9(5):1639–1647

    CAS  PubMed  Google Scholar 

  57. Neri S, Ishii G, Hashimoto H et al (2015) Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma. Int J Cancer 137(4):784–796. doi:10.1002/ijc.29464

    Article  CAS  PubMed  Google Scholar 

  58. Slany A, Haudek-Prinz V, Meshcheryakova A et al (2014) Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma. J Proteome Res 13(2):844–854. doi:10.1021/pr400881p

    Article  CAS  PubMed  Google Scholar 

  59. Garin-Chesa P, Old LJ, Rettig WJ (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 87(18):7235–7239

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Lee HO, Mullins SR, Franco-Barraza J et al (2011) FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 11:245. doi:10.1186/1471-2407-11-245

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Liao D, Luo Y, Markowitz D et al (2009) Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. Plos One 4(11):e7965. doi:10.1371/journal.pone.0007965

    Article  PubMed  PubMed Central  Google Scholar 

  62. Erez N, Truitt M, Olson P et al (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17(2):135–147. doi:10.1016/j.ccr.2009.12.041

    Article  CAS  PubMed  Google Scholar 

  63. Pietras K, Pahler J, Bergers G et al (2008) Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. Plos Med 5(1):e19. doi:10.1371/journal.pmed.0050019

    Article  PubMed  PubMed Central  Google Scholar 

  64. Crawford Y, Kasman I, Yu L et al (2009) PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15(1):21–34. doi:10.1016/j.ccr.2008.12.004

    Article  CAS  PubMed  Google Scholar 

  65. Ehnman M, Missiaglia E, Folestad E et al (2013) Distinct effects of ligand-induced PDGFRalpha and PDGFRbeta signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res 73(7):2139–2149. doi:10.1158/0008-5472.can-12-1646

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Pietras K, Ostman A, Sjoquist M et al (2001) Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61(7):2929–2934

    CAS  PubMed  Google Scholar 

  67. Pietras K, Rubin K, Sjoblom T et al (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62(19):5476–5484

    CAS  PubMed  Google Scholar 

  68. Cooke VG, LeBleu VS, Keskin D et al (2012) Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21(1):66–81. doi:10.1016/j.ccr.2011.11.024

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (1420080). This research was also supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT, and Future Planning (2015R1A1A1A05001209).

Author information

Authors and Affiliations

  1. Department of Pathology, Severance Hospital, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea

    Cheol Keun Park, Woo Hee Jung & Ja Seung Koo

Authors
  1. Cheol Keun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Woo Hee Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ja Seung Koo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ja Seung Koo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 49 kb)

Supplementary material 2 (DOC 53 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Park, C.K., Jung, W.H. & Koo, J.S. Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma. Breast Cancer Res Treat 159, 55–69 (2016). https://doi.org/10.1007/s10549-016-3929-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-016-3929-2

Keywords

Search

Navigation